- Home
- SSL vs BPMC Comparison
SSL vs BPMC Comparison
Compare SSL & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSL
- BPMC
- Stock Information
- Founded
- SSL 1950
- BPMC 2008
- Country
- SSL South Africa
- BPMC United States
- Employees
- SSL N/A
- BPMC N/A
- Industry
- SSL Oil & Gas Production
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- SSL Energy
- BPMC Health Care
- Exchange
- SSL Nasdaq
- BPMC Nasdaq
- Market Cap
- SSL 2.9B
- BPMC 8.3B
- IPO Year
- SSL N/A
- BPMC 2015
- Fundamental
- Price
- SSL $5.19
- BPMC $129.32
- Analyst Decision
- SSL
- BPMC Buy
- Analyst Count
- SSL 0
- BPMC 20
- Target Price
- SSL N/A
- BPMC $127.82
- AVG Volume (30 Days)
- SSL 1.5M
- BPMC 3.3M
- Earning Date
- SSL 01-01-0001
- BPMC 07-31-2025
- Dividend Yield
- SSL N/A
- BPMC N/A
- EPS Growth
- SSL N/A
- BPMC N/A
- EPS
- SSL N/A
- BPMC N/A
- Revenue
- SSL $13,819,021,376.00
- BPMC $562,121,000.00
- Revenue This Year
- SSL N/A
- BPMC $44.46
- Revenue Next Year
- SSL $2.76
- BPMC $32.78
- P/E Ratio
- SSL N/A
- BPMC N/A
- Revenue Growth
- SSL N/A
- BPMC 99.19
- 52 Week Low
- SSL $2.78
- BPMC $73.04
- 52 Week High
- SSL $8.40
- BPMC $129.49
- Technical
- Relative Strength Index (RSI)
- SSL 60.13
- BPMC 76.79
- Support Level
- SSL $4.89
- BPMC $128.06
- Resistance Level
- SSL $5.29
- BPMC $129.49
- Average True Range (ATR)
- SSL 0.15
- BPMC 0.27
- MACD
- SSL 0.02
- BPMC -0.97
- Stochastic Oscillator
- SSL 83.50
- BPMC 87.41
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main businesses: Southern Africa Energy & Chemicals business; and International Chemical business. It generates maximum revenue from the Southern Africa Energy & Chemicals business. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Geographically the company generates the majority of its revenue from South Africa.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.